CLINICOPATHOGENETIC CHARACTERISTICS OF CARDIORENAL SYNDROME IN NON-ALCOHOLIC FATTY DISEASE OF THE LIVER


Cite item

Full Text

Abstract

To study clinicopathogenetic characteristics of cardiorenal syndrome (CRS) in non-alcoholic fatty disease of the liver (nAFDL). Material and methods. Insulin resistance markers, plasma ієрtin and serum adiponectin concentrations, albuminuria, intima-media thickness (IMT) of the common carotid artery (CCA) were assessed in 80 patients with metabolic syndrome (60 males and 20 females, mean age 44+-11 years) and NAFDL. Results. With increasing signs of affection of target organs in NAFDL there was a trend to a significant rise in detection of chronic kidney disease (CKD) and carotid artery atherosclerosis, aggravation of albuminuria and CCA IMT, lowering of glomerular filtration rate. Leptinemia was maximal in CKD patients and directly correlated with albuminuria. Patients with CCA atherosclerosis had a significant fall of serum adiponectin which negatively correlated with CCA IMT. The latter positively correlated with insulinemia, a C-peptide plasma level and HOMA index. Serum concentration of adiponectin positively correlated with DeRitis index. Conclusion. CRS in NAFDL is characterized with frequent development of CKD and CCA atherosclerosis defined also by unbalance of adiponectin and leptin production.

About the authors

M M Severova

I.M. Sechenov First Moscow State Medical University

Email: mseverova@mail.ru
Chair of Therapy and Occupational Medicine of Medicoprophylactic Department

E A Saginova

I.M. Sechenov First Moscow State Medical University

Chair of Therapy and Occupational Medicine of Medicoprophylactic Department

M G Gallyamov

M.V. Lomonosov Moscow State University

Chair of Internal Medicine of Fundamental Medicine Department

N V Ermakov

Research Institute of Medical Ecology

Laboratory of Development of Diagnostic Kits Moscow

A V Rodina

Research Institute of Medical Ecology; I.M. Sechenov First Moscow State Medical University

Chair of Biochemistry Moscow

V V Fomin

I.M. Sechenov First Moscow State Medical University

Email: fomin_vic@mail.ru
Chair of Therapy and Occupational Medicine of Medicoprophylactic Department

N A Mukhin

I.M. Sechenov First Moscow State Medical University

Chair of Therapy and Occupational Medicine of Medicoprophylactic Department

References

  1. Мухин Н. А., Моисеев В. С. Кардиоренальные соотношения и риск сердечно-сосудистых заболеваний. Вестн. РАМН 2003; 11: 50—55.
  2. Шестакова М. В., Ярек-Мартынова И. Р., Иванишина Н. С. и др. Кардиоренальный синдром при сахарном диабете 1-го типа: роль дисфункции эндотелия. Кардиология 2005; 6: 35—41.
  3. Ronco C., McCullough P., Anker S. D. et al. Acute Dialysis Quality Initiative (ADQI) consensus group. Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur. Heart J. 2010; 31(6): 703—711
  4. Лазебник Л. Б., Звенигородская Л. А., Егорова Е. Г. Метаболический синдром у пациентов с заболеваниями органов пищеварения. Тер. арх. 2007; 79 (10): 9—13.
  5. Sowers J.R. The cardiomethabolic syndrome and liver disease. J. Cardiometab. Syndr. 2008; 3: 7—11
  6. Chang Y., Ryu S., Sung E. et al. Nonalcoholic fatty liver disease predicts chronic kidney disease in nonhypertensive and nondiabetic Korean men. Metabolism 2008; 57(4): 569-576.
  7. Goland S., Shimoni S., Zornitzki T. et al. Cardiac abnormalities as a new manifestation of nonalcoholic fatty liver disease: echocardiographic and tissue Doppler imaging assessment. J. Clin. Gastroenterol. 2006; 40 (10): 949-955.
  8. Yasui K., Sumida Y., Mori Y. et al. Nonalcoholic steatohepatitis and increased risk of chronic kidney disease. Metabolism 2011; 60 (5): 735—739.
  9. Комитет экспертов РМОАГ/ВНОК. Диагностика и лечение артериальной гипертензии. (Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов). Систем. гипертензии 2010; 3: 5—26.
  10. Kidney Disease Outcome Quality Initiative. Clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am. J. Kidney Dis. 2002; 39 (Suppl. 2): S1— S246.
  11. Foppa M., Duncan B. B., Rohde L. E. Echocardiography-based left ventricular mass estimation. How should we define hypertrophy? Cardiovasc. Ultrasound 2005; 3: 17.
  12. Чазова И. Е., Литвин А. Ю. Артериальная гипертония и синдром обструктивного апноэ во время сна. В кн:: Чазов Е. И., Чазова И. Е. Руководство по артериальной гипертонии. М.: Media Medica; 2005. 182—200.
  13. Огурцов П. П., Нужный В. П. Экспресс-диагностика (скрининг) хронической алкогольной интоксикации у больных соматического профиля. Клин. фармакол. и тер. 2001; 1: 34—39.
  14. Arase Y., Suzuki F., Kobayashi M. et al. The development of chronic kidney disease in Japanese patients with non-alcoholic fatty liver disease. Intern. Med. 2011; 50(10): 1081—1087.
  15. Kim H. C., Kim D. J., Huh K. B. Association between nonalcoholic fatty liver disease and carotid intima media — thickness according to the presence of metabolic syndrome. Atherosclerosis 2009; 204 (2): 521—525.
  16. Saarikoski L. A., Huupponen R. K., Viikari J. S. et al. Adiponectin is related with carotid artery intima-media thickness and brachial flow-mediated dilatation in young adults — the Cardiovascular Risk in Young Finns Study. Ann. Med. 2010; 42 (8): 603—611.
  17. Huang S. S., Huang P. H., Chen Y. H. et al. Association of adiponectin with future cardiovascular events in patients after acute myocardial infarction. J. Atheroscler. Thromb. 2010; 17 (3): 295—303.
  18. Norata G. D., Raselli S., Grigore L. et al. Leptin:adiponectin ratio is an independent predictor of intima media thickness of the common carotid artery. Stroke 2007; 38 (10): 2844—2846.
  19. Ma H., Gomez V., Lu L. et al. Expression of adiponectin and its receptors in livers of morbidly obese patients with non-alcoholic fatty liver disease. J. Gastroenterol. Hepatol. 2009; 24 (2): 233—237.

Copyright (c) 2012 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies